Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 98

1.

Anti-α-synuclein immunotherapy reduces α-synuclein propagation in the axon and degeneration in a combined viral vector and transgenic model of synucleinopathy.

Spencer B, Valera E, Rockenstein E, Overk C, Mante M, Adame A, Zago W, Seubert P, Barbour R, Schenk D, Games D, Rissman RA, Masliah E.

Acta Neuropathol Commun. 2017 Jan 13;5(1):7. doi: 10.1186/s40478-016-0410-8.

2.

δ-Methyl Branching in the Side Chain Makes the Difference: Access to Room-Temperature Discotics.

Kirres J, Knecht F, Seubert P, Baro A, Laschat S.

Chemphyschem. 2016 Apr 18;17(8):1159-65. doi: 10.1002/cphc.201501166. Epub 2016 Feb 16.

PMID:
26853226
3.

Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson's disease-like models.

Games D, Valera E, Spencer B, Rockenstein E, Mante M, Adame A, Patrick C, Ubhi K, Nuber S, Sacayon P, Zago W, Seubert P, Barbour R, Schenk D, Masliah E.

J Neurosci. 2014 Jul 9;34(28):9441-54. doi: 10.1523/JNEUROSCI.5314-13.2014.

4.

β-Amyloid inhibits E-S potentiation through suppression of cannabinoid receptor 1-dependent synaptic disinhibition.

Orr AL, Hanson JE, Li D, Klotz A, Wright S, Schenk D, Seubert P, Madison DV.

Neuron. 2014 Jun 18;82(6):1334-45. doi: 10.1016/j.neuron.2014.04.039.

5.

Secreted amyloid β-proteins in a cell culture model include N-terminally extended peptides that impair synaptic plasticity.

Welzel AT, Maggio JE, Shankar GM, Walker DE, Ostaszewski BL, Li S, Klyubin I, Rowan MJ, Seubert P, Walsh DM, Selkoe DJ.

Biochemistry. 2014 Jun 24;53(24):3908-21.

6.

Vascular alterations in PDAPP mice after anti-Aβ immunotherapy: Implications for amyloid-related imaging abnormalities.

Zago W, Schroeter S, Guido T, Khan K, Seubert P, Yednock T, Schenk D, Gregg KM, Games D, Bard F, Kinney GG.

Alzheimers Dement. 2013 Oct;9(5 Suppl):S105-15. doi: 10.1016/j.jalz.2012.11.010. Epub 2013 Apr 11.

PMID:
23583235
7.

Axonopathy in an α-synuclein transgenic model of Lewy body disease is associated with extensive accumulation of C-terminal-truncated α-synuclein.

Games D, Seubert P, Rockenstein E, Patrick C, Trejo M, Ubhi K, Ettle B, Ghassemiam M, Barbour R, Schenk D, Nuber S, Masliah E.

Am J Pathol. 2013 Mar;182(3):940-53. doi: 10.1016/j.ajpath.2012.11.018. Epub 2013 Jan 9.

8.

AL amyloid imaging and therapy with a monoclonal antibody to a cryptic epitope on amyloid fibrils.

Wall JS, Kennel SJ, Williams A, Richey T, Stuckey A, Huang Y, Macy S, Donnell R, Barbour R, Seubert P, Schenk D.

PLoS One. 2012;7(12):e52686. doi: 10.1371/journal.pone.0052686. Epub 2012 Dec 26.

9.

Sustained levels of antibodies against Aβ in amyloid-rich regions of the CNS following intravenous dosing in human APP transgenic mice.

Bard F, Fox M, Friedrich S, Seubert P, Schenk D, Kinney GG, Yednock T.

Exp Neurol. 2012 Nov;238(1):38-43. doi: 10.1016/j.expneurol.2012.07.022. Epub 2012 Aug 7.

PMID:
22892246
10.

Neutralization of soluble, synaptotoxic amyloid β species by antibodies is epitope specific.

Zago W, Buttini M, Comery TA, Nishioka C, Gardai SJ, Seubert P, Games D, Bard F, Schenk D, Kinney GG.

J Neurosci. 2012 Feb 22;32(8):2696-702. doi: 10.1523/JNEUROSCI.1676-11.2012.

11.

Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease.

Masliah E, Rockenstein E, Mante M, Crews L, Spencer B, Adame A, Patrick C, Trejo M, Ubhi K, Rohn TT, Mueller-Steiner S, Seubert P, Barbour R, McConlogue L, Buttini M, Games D, Schenk D.

PLoS One. 2011 Apr 29;6(4):e19338. doi: 10.1371/journal.pone.0019338.

12.

Amyloid precursor protein (APP) processing genes and cerebrospinal fluid APP cleavage product levels in Alzheimer's disease.

Bekris LM, Galloway NM, Millard S, Lockhart D, Li G, Galasko DR, Farlow MR, Clark CM, Quinn JF, Kaye JA, Schellenberg GD, Leverenz JB, Seubert P, Tsuang DW, Peskind ER, Yu CE.

Neurobiol Aging. 2011 Mar;32(3):556.e13-23. doi: 10.1016/j.neurobiolaging.2010.10.020. Epub 2010 Dec 31.

13.

Generation and characterization of anti-AA amyloid-specific monoclonal antibodies.

Wall JS, Kennel SJ, Richey T, Allen A, Stuckey A, Weiss DT, Macy SD, Barbour R, Seubert P, Solomon A, Schenk D.

Front Immunol. 2011 Aug 8;2:32. doi: 10.3389/fimmu.2011.00032. eCollection 2011.

14.

The role of animal models in advancing amyloid-beta immunotherapy to the clinic.

Games D, Seubert P.

Alzheimers Res Ther. 2010 Jul 29;2(4):22. doi: 10.1186/alzrt46.

15.

Structural correlates of antibodies associated with acute reversal of amyloid beta-related behavioral deficits in a mouse model of Alzheimer disease.

Basi GS, Feinberg H, Oshidari F, Anderson J, Barbour R, Baker J, Comery TA, Diep L, Gill D, Johnson-Wood K, Goel A, Grantcharova K, Lee M, Li J, Partridge A, Griswold-Prenner I, Piot N, Walker D, Widom A, Pangalos MN, Seubert P, Jacobsen JS, Schenk D, Weis WI.

J Biol Chem. 2010 Jan 29;285(5):3417-27. doi: 10.1074/jbc.M109.045187. Epub 2009 Nov 18.

16.

Abeta immunotherapy: intracerebral sequestration of Abeta by an anti-Abeta monoclonal antibody 266 with high affinity to soluble Abeta.

Yamada K, Yabuki C, Seubert P, Schenk D, Hori Y, Ohtsuki S, Terasaki T, Hashimoto T, Iwatsubo T.

J Neurosci. 2009 Sep 9;29(36):11393-8. doi: 10.1523/JNEUROSCI.2021-09.2009.

17.

Immunotherapy reduces vascular amyloid-beta in PDAPP mice.

Schroeter S, Khan K, Barbour R, Doan M, Chen M, Guido T, Gill D, Basi G, Schenk D, Seubert P, Games D.

J Neurosci. 2008 Jul 2;28(27):6787-93. doi: 10.1523/JNEUROSCI.2377-07.2008.

18.

Progress in the active immunotherapeutic approach to Alzheimer's disease: clinical investigations into AN1792-associated meningoencephalitis.

Pride M, Seubert P, Grundman M, Hagen M, Eldridge J, Black RS.

Neurodegener Dis. 2008;5(3-4):194-6. doi: 10.1159/000113700. Epub 2008 Mar 6. Review.

PMID:
18322388
19.

Antibody capture of soluble Abeta does not reduce cortical Abeta amyloidosis in the PDAPP mouse.

Seubert P, Barbour R, Khan K, Motter R, Tang P, Kholodenko D, Kling K, Schenk D, Johnson-Wood K, Schroeter S, Gill D, Jacobsen JS, Pangalos M, Basi G, Games D.

Neurodegener Dis. 2008;5(2):65-71. doi: 10.1159/000112834. Epub 2008 Jan 4.

PMID:
18182780
20.

Red blood cells are the major source of alpha-synuclein in blood.

Barbour R, Kling K, Anderson JP, Banducci K, Cole T, Diep L, Fox M, Goldstein JM, Soriano F, Seubert P, Chilcote TJ.

Neurodegener Dis. 2008;5(2):55-9. doi: 10.1159/000112832. Epub 2008 Jan 4.

PMID:
18182779
21.

Effect of statins on Alzheimer's disease biomarkers in cerebrospinal fluid.

Riekse RG, Li G, Petrie EC, Leverenz JB, Vavrek D, Vuletic S, Albers JJ, Montine TJ, Lee VM, Lee M, Seubert P, Galasko D, Schellenberg GD, Hazzard WR, Peskind ER.

J Alzheimers Dis. 2006 Dec;10(4):399-406.

PMID:
17183151
22.

Abeta species removal after abeta42 immunization.

Nicoll JA, Barton E, Boche D, Neal JW, Ferrer I, Thompson P, Vlachouli C, Wilkinson D, Bayer A, Games D, Seubert P, Schenk D, Holmes C.

J Neuropathol Exp Neurol. 2006 Nov;65(11):1040-8.

PMID:
17086100
23.

Increased T cell recruitment to the CNS after amyloid beta 1-42 immunization in Alzheimer's mice overproducing transforming growth factor-beta 1.

Buckwalter MS, Coleman BS, Buttini M, Barbour R, Schenk D, Games D, Seubert P, Wyss-Coray T.

J Neurosci. 2006 Nov 1;26(44):11437-41.

24.

Distribution of Abeta peptide in whole blood.

Slemmon JR, Painter CL, Nadanaciva S, Catana F, Cook A, Motter R, Seubert P.

J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Feb 1;846(1-2):24-31. Epub 2006 Aug 30.

PMID:
16939717
25.

Mice as models: transgenic approaches and Alzheimer's disease.

Games D, Buttini M, Kobayashi D, Schenk D, Seubert P.

J Alzheimers Dis. 2006;9(3 Suppl):133-49. Review.

PMID:
16914852
26.

A beta immunotherapy: Lessons learned for potential treatment of Alzheimer's disease.

Schenk DB, Seubert P, Grundman M, Black R.

Neurodegener Dis. 2005;2(5):255-60. Review.

PMID:
16909006
27.

Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease.

Anderson JP, Walker DE, Goldstein JM, de Laat R, Banducci K, Caccavello RJ, Barbour R, Huang J, Kling K, Lee M, Diep L, Keim PS, Shen X, Chataway T, Schlossmacher MG, Seubert P, Schenk D, Sinha S, Gai WP, Chilcote TJ.

J Biol Chem. 2006 Oct 6;281(40):29739-52. Epub 2006 Jul 17.

28.

Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer's disease.

Buttini M, Masliah E, Barbour R, Grajeda H, Motter R, Johnson-Wood K, Khan K, Seubert P, Freedman S, Schenk D, Games D.

J Neurosci. 2005 Oct 5;25(40):9096-101.

29.

Abeta42 immunization in Alzheimer's disease generates Abeta N-terminal antibodies.

Lee M, Bard F, Johnson-Wood K, Lee C, Hu K, Griffith SG, Black RS, Schenk D, Seubert P.

Ann Neurol. 2005 Sep;58(3):430-5.

PMID:
16130106
30.

Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease.

Masliah E, Rockenstein E, Adame A, Alford M, Crews L, Hashimoto M, Seubert P, Lee M, Goldstein J, Chilcote T, Games D, Schenk D.

Neuron. 2005 Jun 16;46(6):857-68.

31.

Amyloid-beta neurotoxicity is mediated by FISH adapter protein and ADAM12 metalloprotease activity.

Malinin NL, Wright S, Seubert P, Schenk D, Griswold-Prenner I.

Proc Natl Acad Sci U S A. 2005 Feb 22;102(8):3058-63. Epub 2005 Feb 14.

32.

Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease.

Masliah E, Hansen L, Adame A, Crews L, Bard F, Lee C, Seubert P, Games D, Kirby L, Schenk D.

Neurology. 2005 Jan 11;64(1):129-31.

PMID:
15642916
33.

Current progress in beta-amyloid immunotherapy.

Schenk D, Hagen M, Seubert P.

Curr Opin Immunol. 2004 Oct;16(5):599-606. Review.

PMID:
15342006
34.

Morphological characterization of Thioflavin-S-positive amyloid plaques in transgenic Alzheimer mice and effect of passive Abeta immunotherapy on their clearance.

Bussière T, Bard F, Barbour R, Grajeda H, Guido T, Khan K, Schenk D, Games D, Seubert P, Buttini M.

Am J Pathol. 2004 Sep;165(3):987-95.

35.

Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer's disease-like neuropathology.

Bard F, Barbour R, Cannon C, Carretto R, Fox M, Games D, Guido T, Hoenow K, Hu K, Johnson-Wood K, Khan K, Kholodenko D, Lee C, Lee M, Motter R, Nguyen M, Reed A, Schenk D, Tang P, Vasquez N, Seubert P, Yednock T.

Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):2023-8. Epub 2003 Feb 3. Erratum in: Proc Natl Acad Sci U S A. 2004 Aug 3;101(3):11526.

36.

Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy.

Bacskai BJ, Kajdasz ST, McLellan ME, Games D, Seubert P, Schenk D, Hyman BT.

J Neurosci. 2002 Sep 15;22(18):7873-8.

37.

Potential treatment opportunities for Alzheimer's disease through inhibition of secretases and Abeta immunization.

Schenk D, Games D, Seubert P.

J Mol Neurosci. 2001 Oct;17(2):259-67. Review.

PMID:
11816797
38.

Immunotherapy with beta-amyloid for Alzheimer's disease: a new frontier.

Schenk D, Seubert P, Ciccarelli RB.

DNA Cell Biol. 2001 Nov;20(11):679-81.

PMID:
11788045
39.

Encapsulation in biodegradable microparticles enhances serum antibody response to parenterally-delivered beta-amyloid in mice.

Brayden DJ, Templeton L, McClean S, Barbour R, Huang J, Nguyen M, Ahern D, Motter R, Johnson-Wood K, Vasquez N, Schenk D, Seubert P.

Vaccine. 2001 Jul 20;19(30):4185-93.

PMID:
11457544
40.

Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy.

Bacskai BJ, Kajdasz ST, Christie RH, Carter C, Games D, Seubert P, Schenk D, Hyman BT.

Nat Med. 2001 Mar;7(3):369-72. No abstract available.

PMID:
11231639
41.

Prevention and reduction of AD-type pathology in PDAPP mice immunized with A beta 1-42.

Games D, Bard F, Grajeda H, Guido T, Khan K, Soriano F, Vasquez N, Wehner N, Johnson-Wood K, Yednock T, Seubert P, Schenk D.

Ann N Y Acad Sci. 2000;920:274-84.

PMID:
11193164
42.

Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain.

Dovey HF, John V, Anderson JP, Chen LZ, de Saint Andrieu P, Fang LY, Freedman SB, Folmer B, Goldbach E, Holsztynska EJ, Hu KL, Johnson-Wood KL, Kennedy SL, Kholodenko D, Knops JE, Latimer LH, Lee M, Liao Z, Lieberburg IM, Motter RN, Mutter LC, Nietz J, Quinn KP, Sacchi KL, Seubert PA, Shopp GM, Thorsett ED, Tung JS, Wu J, Yang S, Yin CT, Schenk DB, May PC, Altstiel LD, Bender MH, Boggs LN, Britton TC, Clemens JC, Czilli DL, Dieckman-McGinty DK, Droste JJ, Fuson KS, Gitter BD, Hyslop PA, Johnstone EM, Li WY, Little SP, Mabry TE, Miller FD, Audia JE.

J Neurochem. 2001 Jan;76(1):173-81.

43.

Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease.

Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B, Seubert P, Schenk D, Yednock T.

Nat Med. 2000 Aug;6(8):916-9.

PMID:
10932230
44.

beta-peptide immunization: a possible new treatment for Alzheimer disease.

Schenk DB, Seubert P, Lieberburg I, Wallace J.

Arch Neurol. 2000 Jul;57(7):934-6. Review. No abstract available.

PMID:
10891974
45.

Effects of time and cholinesterase inhibitor treatment on multiple cerebrospinal fluid parameters in Alzheimer's disease.

Moriearty PL, Seubert P, Galasko D, Markwell S, Unni L, Vicari S, Becker RE.

Methods Find Exp Clin Pharmacol. 1999 Oct;21(8):549-54.

PMID:
10599054
46.

Purification and cloning of amyloid precursor protein beta-secretase from human brain.

Sinha S, Anderson JP, Barbour R, Basi GS, Caccavello R, Davis D, Doan M, Dovey HF, Frigon N, Hong J, Jacobson-Croak K, Jewett N, Keim P, Knops J, Lieberburg I, Power M, Tan H, Tatsuno G, Tung J, Schenk D, Seubert P, Suomensaari SM, Wang S, Walker D, Zhao J, McConlogue L, John V.

Nature. 1999 Dec 2;402(6761):537-40.

PMID:
10591214
47.

Alterations in synaptic transmission and long-term potentiation in hippocampal slices from young and aged PDAPP mice.

Larson J, Lynch G, Games D, Seubert P.

Brain Res. 1999 Sep 4;840(1-2):23-35.

PMID:
10517949
48.

Longitudinal stability of CSF tau levels in Alzheimer patients.

Sunderland T, Wolozin B, Galasko D, Levy J, Dukoff R, Bahro M, Lasser R, Motter R, Lehtimäki T, Seubert P.

Biol Psychiatry. 1999 Sep 15;46(6):750-5.

PMID:
10494442
49.

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse.

Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S, Wogulis M, Yednock T, Games D, Seubert P.

Nature. 1999 Jul 8;400(6740):173-7.

PMID:
10408445
50.

Apolipoprotein E epsilon 4 allele in association with global cognitive performance and CSF markers in Alzheimer's disease.

Lasser RA, Dukoff R, Levy J, Levin R, Lehtimäki T, Seubert P, Sunderland T.

Int J Geriatr Psychiatry. 1998 Nov;13(11):767-74.

PMID:
9850873

Supplemental Content

Loading ...
Support Center